Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$15.59 -0.6%	$18.24	$14.33 ▼ $55.70	$1.60B	0.95	1.26 million shs	4.06 million shs
IDYA IDEAYA Biosciences	$22.28 +1.6%	$18.79	$13.45 ▼ $44.42	$1.95B	0.04	1.02 million shs	1.39 million shs
INDV Indivior	$13.93 +2.0%	$11.21	$7.33 ▼ $16.98	$1.92B	0.66	1.09 million shs	865,493 shs
NWBO Northwest Biotherapeutics	$0.26 -0.8%	$0.27	$0.17 ▼ $0.50	$377.18M	-1.09	3.65 million shs	2.14 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	-0.35%	-3.41%	-20.05%	-46.68%	-53.83%
IDYA IDEAYA Biosciences	+1.64%	+5.59%	+27.68%	+19.91%	-43.47%
INDV Indivior	+1.98%	+2.50%	+24.49%	+43.90%	-17.33%
NWBO Northwest Biotherapeutics	-0.76%	+4.00%	-9.72%	+6.56%	-39.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHVN Biohaven	3.029 of 5 stars	4.5	1.0	0.0	1.8	2.5	0.6
IDYA IDEAYA Biosciences	4.0047 of 5 stars	3.5	2.0	4.4	3.3	1.7	0.0
INDV Indivior	2.5014 of 5 stars	1.6	5.0	0.0	3.0	1.7	1.9
NWBO Northwest Biotherapeutics	0.1106 of 5 stars	0.0	2.0	0.0	1.9	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHVN Biohaven	3.07	Buy	$59.46	281.41% Upside
IDYA IDEAYA Biosciences	2.93	Moderate Buy	$54.27	143.59% Upside
INDV Indivior	3.25	Buy	$15.00	7.68% Upside
NWBO Northwest Biotherapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NWBO, INDV, BHVN, and IDYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $66.00
5/19/2025	BHVN Biohaven	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$54.00 ➝ $21.00
5/13/2025	BHVN Biohaven	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	BHVN Biohaven	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$61.00 ➝ $54.00
4/28/2025	BHVN Biohaven	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $57.00
4/24/2025	BHVN Biohaven	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/20/2025	BHVN Biohaven	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$60.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHVN Biohaven	N/A	N/A	N/A	N/A	$5.34 per share	N/A
IDYA IDEAYA Biosciences	$7M	278.76	N/A	N/A	$12.10 per share	1.84
INDV Indivior	$1.17B	1.64	$2.82 per share	4.94	N/A	∞
NWBO Northwest Biotherapeutics	$1.93M	195.43	N/A	N/A	($0.06) per share	-4.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHVN Biohaven	-$408.17M	-$9.36	N/A	N/A	N/A	N/A	-225.12%	-158.89%	8/5/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.59	N/A	N/A	N/A	N/A	-26.74%	-25.54%	8/5/2025 (Estimated)
INDV Indivior	$2M	-$0.31	N/A	8.15	N/A	-3.96%	-241.73%	15.09%	7/24/2025 (Estimated)
NWBO Northwest Biotherapeutics	-$62.60M	-$0.07	N/A	∞	N/A	-4,666.29%	N/A	-261.36%	8/7/2025 (Estimated)

Latest NWBO, INDV, BHVN, and IDYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	NWBO Northwest Biotherapeutics	N/A	-$0.01	N/A	-$0.01	N/A	$0.38 million
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/6/2025	Q1 2025	IDYA IDEAYA Biosciences	-$0.75	-$0.82	-$0.07	-$0.82	$2.10 million	N/A
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million
3/31/2025	Q4 2024	NWBO Northwest Biotherapeutics	N/A	-$0.02	N/A	-$0.02	N/A	$0.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
NWBO Northwest Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHVN Biohaven	N/A	2.89	2.89
IDYA IDEAYA Biosciences	N/A	14.97	22.93
INDV Indivior	N/A	0.83	0.65
NWBO Northwest Biotherapeutics	N/A	0.09	0.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHVN Biohaven	88.78%
IDYA IDEAYA Biosciences	98.29%
INDV Indivior	60.33%
NWBO Northwest Biotherapeutics	0.04%

Insider Ownership

Company	Insider Ownership
BHVN Biohaven	16.00%
IDYA IDEAYA Biosciences	2.50%
INDV Indivior	N/A
NWBO Northwest Biotherapeutics	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHVN Biohaven	239	102.11 million	84.94 million	Optionable
IDYA IDEAYA Biosciences	80	87.58 million	84.47 million	Optionable
INDV Indivior	1,164	137.88 million	N/A	Not Optionable
NWBO Northwest Biotherapeutics	20	1.45 billion	1.24 billion	Not Optionable

NWBO, INDV, BHVN, and IDYA Headlines

Recent News About These Companies

Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments

June 11 at 12:49 PM | prnewswire.com

Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Pass Below 200-Day Moving Average - Time to Sell?

June 7, 2025 | marketbeat.com

Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?

May 31, 2025 | marketbeat.com

Northwest Biotherapeutics: A Spike On Their Expected Imminent Approval

April 22, 2025 | seekingalpha.com

Citadel Securities, Virtu Must Face Biotech Stock Spoof Suit (1)

March 29, 2025 | news.bloomberglaw.com

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments

January 13, 2025 | msn.com

Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing

December 26, 2024 | prnewswire.com

Northwest Biotherapeutics: All Is Not Well With This One

December 14, 2024 | seekingalpha.com

Behind the Bell: Arcutis Biotherapeutics

November 5, 2024 | nasdaq.com

Northwest Registered Agent Review 2024: Features, Pricing & More

October 24, 2024 | forbes.com

0K95.IL,0P0000AFQ5,0 (0K95.IL)

September 14, 2024 | nz.finance.yahoo.com

Traders News Digs into the Biotech Space and Releases New Feature Profile

August 15, 2024 | br.advfn.com

Northwest Biotherapeutics addresses rumors and market activity

August 4, 2024 | uk.investing.com

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities

July 3, 2024 | prnewswire.com

Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property

June 17, 2024 | prnewswire.com

Northwest Biotherapeutics Inc (NWBO) Dividend History

May 25, 2024 | nasdaq.com

Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors

March 21, 2024 | prnewswire.com

‘Spoofing’ case might draw back curtain on high-speed trading firms

March 2, 2024 | ft.com

Northwest Biotherapeutics, Inc. (NWBO)

February 29, 2024 | uk.finance.yahoo.com

Northwest Biotherapeutics Stock (OTC:NWBO), Short Interest Report

February 23, 2024 | benzinga.com

Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification

February 7, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NWBO, INDV, BHVN, and IDYA Company Descriptions

Biohaven NYSE:BHVN

$15.59 -0.10 (-0.64%)

Closing price 06/12/2025 03:58 PM Eastern

Extended Trading

$15.42 -0.18 (-1.12%)

As of 08:21 AM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

IDEAYA Biosciences NASDAQ:IDYA

$22.28 +0.36 (+1.64%)

Closing price 06/12/2025 04:00 PM Eastern

Extended Trading

$22.00 -0.28 (-1.23%)

As of 07:05 AM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Indivior NASDAQ:INDV

$13.93 +0.27 (+1.98%)

As of 06/12/2025 04:00 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Northwest Biotherapeutics OTCMKTS:NWBO

$0.26 0.00 (-0.76%)

As of 06/12/2025 03:59 PM Eastern

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time